Select Medical Receives Positive Rating and $48 Price Target in Latest Benchmark Report
November 6, 2024
☀️Trending News
Select Medical ($NYSE:SEM) is a leading healthcare provider in the United States, offering specialized services to patients in need of rehabilitation, long-term acute care, and outpatient therapy. In their latest research report, Benchmark reaffirmed their “buy” rating for Select Medical, citing the company’s strong financial performance and positive market outlook. This growth was driven by a strong demand for Select Medical’s services, as well as efficient cost management strategies.
Additionally, Benchmark noted that Select Medical has a strong competitive advantage in the healthcare industry due to its specialized and diversified services. The company’s various segments, including rehabilitation hospitals, long-term acute care hospitals, and outpatient clinics, provide a range of high-quality care options for patients. This not only allows Select Medical to serve a larger market but also creates a more stable revenue stream for the company. The report also highlighted Select Medical’s strong financial position and its ability to weather potential economic downturns. The company has a solid balance sheet with low levels of debt and a healthy cash position, providing it with the flexibility to invest in growth opportunities and withstand any potential challenges. With its strong financial performance, diversified services, and solid market position, Select Medical is well-positioned to continue delivering value to its shareholders and patients alike.
Market Price
On Friday, shares of SELECT MEDICAL (NYSE: SEM) experienced a significant surge after the release of a new benchmark report. This news caused the stock to open at $34.3 and close at $35.95, representing a 12.06% increase from the previous day’s closing price of $32.08. SELECT MEDICAL operates a network of specialized hospitals and outpatient rehabilitation centers, providing high-quality post-acute care to patients across the United States. The company has shown consistent growth and profitability in recent years, making it an attractive investment opportunity for many investors. The benchmark report highlighted SELECT MEDICAL’s strong financials and their ability to adapt to changes in the healthcare industry. This adaptability has been crucial in maintaining the company’s success, especially during the global pandemic. Despite challenges faced by the healthcare sector, SELECT MEDICAL has continued to deliver strong financial results, which has been recognized by the research firm’s positive rating and price target.
Moreover, the report also noted SELECT MEDICAL’s strong leadership and management team, who have played a pivotal role in driving the company’s growth and success. Their strategic decision-making and focus on providing quality patient care have been key factors in maintaining the company’s strong financial position. Investors have responded positively to this news, as reflected in the sharp increase in SELECT MEDICAL’s stock price. This shows confidence in the company’s future growth potential and confirms the research firm’s positive assessment. With its solid financials, strong leadership, and ability to adapt to changes in the healthcare industry, SELECT MEDICAL is well-positioned for long-term success. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Select Medical. More…
| Total Revenues | Net Income | Net Margin |
| 6.66k | 234.72 | 3.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Select Medical. More…
| Operations | Investing | Financing |
| 582.06 | -268.48 | -327.48 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Select Medical. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 7.69k | 6.12k | 10.04 |
Key Ratios Snapshot
Some of the financial key ratios for Select Medical are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.4% | -0.8% | 8.7% |
| FCF Margin | ROE | ROA |
| 5.3% | 28.4% | 4.7% |
Analysis
After conducting a thorough analysis of the financials of SELECT MEDICAL, I have determined that it falls into the category of a ‘rhino’ company on our Star Chart. This classification indicates that SELECT MEDICAL has achieved moderate revenue or earnings growth, making it a solid investment option for certain types of investors. Overall, SELECT MEDICAL appears to be a strong company with a high health score of 8/10. This is largely due to its impressive cashflows and manageable levels of debt. These aspects of the company make it well-equipped to weather any potential financial crises in the future and continue operating successfully. One area where SELECT MEDICAL stands out is in its dividend, which can be appealing to investors seeking a steady income stream from their investments. Additionally, the company’s growth potential is also rated as medium, indicating that there may be room for further expansion and increased profits in the future. In terms of profitability, SELECT MEDICAL appears to be on solid ground. However, it should be noted that the company’s asset score is relatively weak. This could potentially be a concern for investors who place a high emphasis on a company’s tangible assets. Overall, I believe that SELECT MEDICAL would be an attractive option for investors who are looking for a stable, profitable company with strong cashflows and manageable levels of debt. Its moderate growth potential, dividend offering, and solid health score make it a promising investment opportunity. More…
Peers
The company’s competitors include Eukedos SpA, Med Life SA, Athens Medical Centre SA, and other similar companies.
– Eukedos SpA ($LTS:0Q8E)
Eukedos SpA is a pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of rare diseases. The company has a market cap of 28.09M as of 2022 and a Return on Equity of 10.29%. Eukedos SpA is headquartered in Milan, Italy.
– Med Life SA ($LTS:0RO5)
MedLife SA is a publicly traded company with a market capitalization of 2B as of 2022. The company’s return on equity is 22.48%. MedLife SA is a leading provider of medical and healthcare services in South America. The company offers a full range of services including primary care, hospital care, specialty care, and behavioral health services. MedLife SA also has a strong presence in the insurance and managed care markets.
– Athens Medical Centre SA ($LTS:0ONM)
Athens Medical Centre SA is a medical company that operates in Greece. The company has a market cap of 117.53M as of 2022 and a return on equity of 18.02%. The company provides medical services and products to patients in Greece. Athens Medical Centre SA operates in the following segments: Medical Services, Medical Products, and Other. The Medical Services segment provides medical services to patients in Greece. The Medical Products segment provides medical products to patients in Greece. The Other segment includes activities such as real estate and investments.
Summary
Select Medical received a “buy” rating and a $48.00 price target from Benchmark in a recent research report. This had a positive impact on the company’s stock price, as it increased on the same day. This analysis suggests that Select Medical may be a good investment opportunity, as the target price indicates potential for growth.
However, without further elaboration on the company’s background, it is difficult to fully assess the viability of this investment. Investors should conduct further research and consider various factors before making any investment decisions regarding Select Medical.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
